Sareum Holdings (AIM: SAR)

Last close As at 20/12/2024

GBP0.27

−0.50 (−1.82%)

Market capitalisation

GBP34m

Sareum is a UK-based drug development company, specialising in small molecule kinase inhibitors. Its flagship programmes are its pre-clinical TYK2/JAK1 inhibitors, SDC-1801 for autoimmune diseases and SDC-1802 for cancer. SDC-1801 is undergoing advanced dose finding and toxicology studies with a target to file a CTA in mid-2021. Other programmes include the CHK1 inhibitor SRA737 (Sareum holds a 27.5% economic interest), previously out licensed to Sierra Oncology and the de-prioritised FLT3+Aurora kinase.

Latest Insights

View More

Healthcare | edison tv

Sareum Holdings – executive interview

Healthcare | Update

Sareum Holdings — SDC-1801 prepping to enter Phase II

Healthcare | Flash note

Sareum Holdings — New funding extends runway to Phase II

Healthcare | Flash note

Sareum Holdings — SDC-1801 records positive Phase Ia data

Sareum Holdings_resized

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Analyst

Key Management

  • John Reader

    CSO

  • Stephen Parker

    Chairman

  • Tim Mitchell

    CEO

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free